clogP cLogP of 2 and SR144528 were calculated in MarvinSketch 17.6 using the ChemAxon Method and electrolyte concentrations of 0.1 mol/dm 3 of Cland Na + K + . Synthesis of all other compounds not reported within manuscript 6-Bromo-N-(4-methylcyclohexyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8naphthyridine-3-carboxamide (1) To a stirred solution of 5 (22 mg, 59.9 µmol) in DMF (1 mL) was added caesium carbonate (55 mg, 0.17 mmol). After stirring for 1 h, 4-(2-chloroethyl)morpholine hydrochloride (22 mg, 0.12 mmol) was added. The mixture was stirred at 50 °C for 12 h and upon cooling was evaporated under reduced pressure. Saturated aq. NaHCO3 was added until pH 10-11 and then extracted with DCM (3 x 20 mL). The combined organics were washed with H2O (1 x 60 mL), dried over MgSO4 and evaporated under reduced pressure. The crude product was purified by crystallisation in ACN to yield 1 (10.5 mg, 22.0 µmol, 37%), as a yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.80 (m, 1H, NH isomer A), 9.41 (m, 1H, NH isomer B) 8.80 (s, 1H, ArH), 8.69 (d, J = 2.3 Hz, 1H, ArH), 8.19 (t, J = 2.1 Hz, 1H, ArH), 5.04 -4.58 (m, 2H, N1-CH2), 4.32 -3.91 (m, 1H, NHCH isomer A and NHCH isomer B), 3.92 -3.55 (m, 4H, N-CH2 morpholino), 3.40 -2.22 (m, 6H, N1-CH2CH2 & O-CH2 morpholino), 2.12 -0.88 (m, 12H, CH & CH2 cyclohexyl, CH3). Isomers A and B represent cis/trans (in no defined order) isomers. Data matches the literature reference. A and B resolved as separate peaks in some instances, but are not assigned. HRMS-ESI calculated for C22H30BrN4O3 [M+H] + 477.1496, found m/z 477.1462. Analytical RP-HPLC Rt = 15.57 min (57%) and 15.84 min (43%).
22%), as a white solid. 1 H NMR (400 MHz, CDCl3) δ 9.93 (d, J = 7.8 Hz, 1H, NH isomer A), 9.55 (d, J = 8.1 Hz, 1H, NH isomer B), 8.79 (s, 1H, ArH), 8.70 (d, J = 2.4 Hz, 1H, ArH), 8.17 (dd, J = 3.5, 2.4 Hz, 1H, ArH), 2H, , 4.25 (m, 1H, NHCH isomer A), 3 .9 (m, 1H, NHCH isomer B), 3.67 (s, 3H, 2H, CH2COOMe), 16H, CH & CH2 cyclohexyl & CH3) . Isomers A and B represent cis/trans (in no defined order) isomers. 13 C NMR (101 MHz, CDCl3) δ 173. 92, 173.87, 162.34, 162.29, 161.55, 161.53, 152.77, 152.72, 148.34, 148.28, 140.76, 140.58, 139.83, 139.79, 124.47, 124.38, 116.25, 116.24, 114.27, 114.21, 51.71, 51.70, 49.03, 45.83, 41.80, 41.72, 34.01, 33.83, 33.82, 33.07, 32.12, 31.21, 30.30, 29.72, 27.48, 27.47, 22.47, 22.45, 22.36, 21.67 . Isomers A and B resolved as separate peaks in some instances, but are not assigned. HRMS-ESI calculated for C22H28BrN3NaO4 [M+Na] + 500.1155, found m/z 500.1117. Analytical RP-HPLC Rt = 23.16 min (50%) and 24.15 min (50%).
Methyl 4-({6-bromo-3-[(4-methylcyclohexyl)carbamoyl]-2-oxo-1,2-dihydro-1,8naphthyridin-1-yl}methyl)benzoate (7)
A solution of 5 (75 mg, 0.23 mmol), caesium carbonate (206 mg, 0.63 mmol) and methyl 4bromomethylbenzoate (104 mg, 0.45 mmol) in DMF (1.1 mL) was reacted as described in the procedure for 6. The crude residue was purified by flash silica gel column chromatography (99:1 DCM/MeOH) and a portion (6 mg) of the solid obtained (20 mg) was further purified by semi-preparative RP-HPLC to yield 7 (3.54 mg, 6.93 µmol) , as a white solid. 1 H NMR (400 MHz, CDCl3) δ 9. 1H, NH isomer A), 1H, NH isomer B), 8.84 (s, 1H, ArH), 1H, ArH), 1H, ArH), 2H, ArH Ph), 2H, ArH Ph), 5.81 (d, J = 8.6 Hz, 2H, N1-CH2), 4.37 -4.16 (m, 1H, NHCH), 15H, CH & CH2 cyclohexyl, CH3) . Isomers A and B represent cis/trans (in no defined order) isomers. HRMS-ESI calculated for C25H26BrN3NaO4 [M+Na] + 534.0999, found m/z 534.1008. Analytical RP-HPLC Rt = 24.16 min (50%) and 24.44 min (50%).
Methyl 5-[6-(4-methoxyphenyl)-3-[(4-methylcyclohexyl)carbamoyl]-2-oxo-1,2-dihydro-1,8-naphthyridin-1-yl]pentanoate (8)
Compound 6 (16 mg, 32.8 µmol), 4-methoxyphenylboronic acid (6.5 mg, 42 .7 µmol) and Na2CO3 (9.1 mg, 85.4 µmol) were dissolved in a 1:4 v:v mixture of H2O and DMF (1.5 mL) . Pd(OAc)2 (0.08 mg, 0.33 µmol) was added and the reaction mixture heated to 110 °C and stirred for 3 h, then cooled to rt and diluted with H2O (1.5 mL). The aqueous phase was extracted with EA (4 x 1.5 mL) and the combined organics washed with H2O (3 x 6 mL) and sat. aq. NaCl (1 x 6 mL), dried over MgSO4 and evaporated under reduced pressure. The crude product was purified by flash silica gel column chromatography (2:1 hexane/EA) to yield the desired 8 (9.2 mg, 18.1 µmol, 55%), as a yellow solid (Rf 0.5, 1:1 hexane/EA). 1 04, 173.99, 162.56, 162.52, 162.10, 160.07, 160.06, 150.63, 150.58, 148.57, 148.51, 142.07, 141.89, 135.46, 135.43, 132.28, 132.22, 128.96, 128.92, 128.27, 123.56, 123.47, 114.93, 114.83, 55.58, 51.73, 51.70, 48.94, 45.80, 41.66, 41.57, 34.21, 34.05, 33.93, 33.91, 33.61, 33.11, 32.14, 31.20, 30.34, 29.75, 28.21, 27.61, 22.56, 22.53, 22.39, 21.65, 21.36 . Isomers A and B resolved as separate peaks in some instances, but are not assigned. HRMS-ESI calculated for C29H35N3NaO5 [M+Na] + 528.2469, found m/z 528.2475. Analytical RP-HPLC Rt = 24.33 min (50%) and 25.08 min (50%).
5-{6-Bromo-3-[(4-methylcyclohexyl)carbamoyl]-2-oxo-1,2-dihydro-1,8-naphthyridin-1-yl}pentanoic acid (9)
A solution of 6 (60 mg, 0.13 mmol) and 10% NaOH (10 mL) was heated to 110 °C for 5 h.
The mixture was cooled and conc. HCl added until pH 2-3. The precipitate was filtered and treated with diethyl ether to yield 9 (25 mg, 54.5 µmol, 43%) as a white solid (Rf 0.34, 1:1 hexane/EA). 1 34, 178.28, 162.35, 162.30, 161.70, 161.69, 152.84, 152.80, 148.31, 148.26, 140.98, 140.81, 139.92, 139.88, 124.30, 124.21, 116.26, 116.25, 114.34, 114.28, 49.11, 45.91, 41.75, 41.67, 33.99, 33.65, 33.64, 33.04, 32.10, 31.20, 30.28, 29.84, 29.71, 27.40, 22.36, 22.21, 22.19, 21.68 . Isomers A and B resolved as separate peaks in some instances, but are not assigned. HRMS-ESI calculated for C21H26BrN3NaO4
[M+Na] + 486.0999, found m/z 486.1007.
tert-Butyl N-[8-(5-{6-bromo-3-[(4-methylcyclohexyl)carbamoyl]-2-oxo-1,2-dihydro-1,8-

naphthyridin-1-yl}pentanamido)octyl]carbamate (10)
To a solution of 9 (13 mg, 27.8 µmol) in anhydrous DMF (2 mL) were added DIPEA (14.5 µL, 85 µmol) and HATU (11 mg, 27.8 µmol). After stirring for 5 min, a solution of tertbutyl-N-(8-aminooctyl)carbamate (prepared according to a literature procedure) 2 (22 mg, 88.8 µmol) and DIPEA (14.5 µL, 85 µmol) in DMF (1.5 mL) was added. The reaction mixture was stirred for 14 hand then the solvent evaporated under reduced pressure. The crude residue was purified by flash silica gel column chromatography (1:1 hexane/EA) to yield 10 (14 mg, 19.6 µmol, 71%) as a grey solid (Rf 0.484 1:2 hexane/EA). 1 66, 163.62, 163.41, 154.11, 149.57, 142.26, 141.71, 124.66, 117.54, 117.51, 115.28, 115.24, 79.74, 50.33, 49.64, 49.43, 49.21, 49.00, 48.79, 48.57, 48.36, 46.69, 42.76, 42.66, 41.35, 40.76, 40.34, 40.23, 36.71, 36.67, 34.96, 33.82, 33.16, 32.69, 31.08, 30.95, 30.74, 30.35, 30.32, 30.09, 30.02, 28.80, 28.53, 28.39, 28.36, 27.91, 27.81, 27.77, 27.34, 24.43, 24.40, 22.56 
tert-Butyl N-(2-{2-[2-(5-{6-bromo-3-[(4-methylcyclohexyl)carbamoyl]-2-oxo-1,2-
dihydro-1,8-naphthyridin-1-yl}pentanamido)ethoxy]ethoxy}ethyl)carbamate (11)
Compound 9 (8.9 mg, 19.2 µmol), DIPEA (20.1 µL, 0.12 mmol), HATU (7.3 mg, 19.2 µmol) and tert-butyl N-{2- [2-(2-aminoethoxy) ethoxy]-ethyl}carbamate (prepared according to literature procedure) 3 (15 mg, 62.0 µmol) in DMF (1.8 mL) were used as described in the procedure for 10. The crude product was purified by flash silica gel column chromatography (1:7 hexane/EA) to yield 11 (10 mg, 14.7 µmol, 77%) as a grey solid (Rf 0.19 1:2 hexane/EA). 1 Isomers A and B represent cis/trans (in no defined order) isomers. 13 C NMR (101 MHz, CDCl3) δ 162. 31, 162.27, 161.65, 152.89, 152.86, 148.27, 140.83, 140.66, 139.86, 139.82, 124.33, 124.24, 116.24, 114.31, 114.25, 70.47, 70.36, 70.25, 70.10, 49.07, 45.88, 41.87, 39.60, 36.14, 33.99, 33.07, 32.11, 30.29, 29.71, 28.55, 27.53, 23.33, 22.36, 21.69 . Isomers A and B resolved as separate peaks in some instances, but are not assigned. HRMS-ESI calculated for C32H49BrN5O7 [M+H] + 694.2810, found m/z 694.2870.
1-{4-[(8-Aminooctyl)carbamoyl]butyl}-6-bromo-N-(4-methylcyclohexyl)-2-oxo-1,2-
dihydro-1,8-naphthyridine-3-carboxamide (12)
Compound 10 (11 mg, 16.1 µmol) was dissolved in DCM (0.9 mL) and TFA (0.9 mL) was added. After 1 h stirring, the reaction mixture was evaporated under N2 stream, followed by reduced pressure. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of 12 (11.9 mg, 14.6 µmol, 91%) as a white solid. HRMS-ESI calculated for C29H45BrN5O3 [M+H] + 590.2700, found m/z 590.2703. Analytical RP-HPLC Rt = 18.12 min (40%) and 18.27 min (60%).
1-[4-({2-[2-(2-Aminoethoxy)ethoxy]ethyl}carbamoyl)butyl]-6-bromo-N-(4methylcyclohexyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide (13)
A solution of 11 (8.0 mg, 11.5 µmol) and TFA (1.2 mL) in DCM (1.2 mL) was reacted as described in the procedure for 12. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of 13 (8.1 mg, 9.8 µmol, 86%) as a white solid. HRMS-ESI calculated for C27H41BrN5O5 [M+H] + 594.2286, found m/z 594.2294. Analytical RP-HPLC Rt = 16.84 min (51%) and 17.01 min (49%).
6-Bromo-1-{4-[(8-acetamidooctyl)carbamoyl]butyl}-N-(4-methylcyclohexyl)-2-oxo-1,2-
dihydro-1,8-naphthyridine-3-carboxamide (14)
To a solution of the TFA salt of 12 (2.4 mg, 2.9 µmol) and DIPEA (1.9 µL, 10.9 µmol, added as a 1:10 solution in DCM) in DCM (500 µL) was added acetic anhydride (0.28 µL, 3.0 µmol, added as a 1:10 solution in DCM) and the mixture stirred at rt for 1 h. The reaction solvent was evaporated under N2 stream. The product was purified by semi-preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, yielding 14 (1.76 mg, 2.8 µmol, 95%) as a white solid. HRMS-ESI calculated for C31H46BrN5NaO4
[M+Na] + 654.2625, found m/z 654.2612. Analytical RP-HPLC Rt = 21.04 min (40%) and 21.20 min (60%). The TFA salt of 13 (1.53 mg, 1.9 µmol), DIPEA (1.2 µL, 6.9 µmol), and acetic anhydride (0.18 µL, 1.9 µmol) in DCM (437 µL) were treated as in the procedure for 14. The product was purified by semi-preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, yielding 15 (1.14 mg, 1.8 µmol, 96%) as a white solid.
6-Bromo
HRMS-ESI calculated for C29H42BrN5NaO6
[M+Na] + 658.2211, found m/z 658.2191.
Analytical RP-HPLC Rt = 18.90 min (53%) and 19.11 min (47%). The TFA salt of 13 (5.32 mg, 6.5 µmol), DIPEA (2.8 µL, 15.9 µmol), BODIPY 630/650-X-OSu (1.25 mg, 1.89 µmol) and DMF (844 µL) were reacted as described in the procedure for 16. The crude product was purified by semi-preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, yielding 17 (1.9 mg, 1.7 µmol, 88%) as a bright blue solid. HRMS-ESI calculated for C56H66BBrF2N8NaO8S [M+Na] + 1161.3870, found m/z 1161.3780. Analytical RP-HPLC Rt = 24.39 min (55%) and 24.50 min (45%).
6-Bromo
Compounds 19, 20 detailed in manuscript.
trans-N-(4-Hydroxycyclohexyl)-6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-
1,2-dihydro-1,8-naphthyridine-3-carboxamide (21)
To a stirred solution of 19 (800 mg, 2.0 mmol) in anhydrous DMF (40 mL) was added DIPEA (2 mL, 11.8 mmol) and HATU (743 mg, 2.0 mmol). The reaction mixture was stirred for 5 min, then trans-4-aminocyclohexanol hydrochloride (675 mg, 5.9 mmol) in DMF (40 mL) was added and the mixture stirred for 42 h. The DMF was evaporated under reduced pressure and the residue taken up in H2O (50 mL) and extracted with DCM (3 x 50 mL). The combined organics were washed with H2O (2 x 60 mL), dried over MgSO4, filtered and evaporated under reduced pressure. The crude was purified by precipitation in ACN, yielding 21 (815 mg, 1.6 mmol, 82%) as a yellow solid. 1 57, 162.30, 160.11, 150.64, 148.65, 142.24, 135.44, 132.36, 128.85, 128.26, 123.24, 114.95, 114.78, 69.93, 67.15, 56.04, 55.58, 54.05, 47.94, 39.13, 34.04, 30.67. HRMS-ESI calculated for C28H35N4O5 [M+H] + 507.2602, found m/z 507.2571. Analytical RP-HPLC Rt = 13.85 min. N-[(1s,4s)-4-[6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2- 
tert-Butyl
dihydro-1,8-naphthyridine-3-amido]cyclohexyl]carbamate (22)
Compound 19 (experimental detailed in manuscript) (50 mg, 0.12 mmol), DIPEA (128 µL, 0.73 mmol), HATU (46 mg, 0.12 mmol) and 1-N-Boc-cis-1,4-cyclohexyldiamine (79 mg, 0.37 mmol) in DMF (2.5 mL) were used as described in the procedure for 10. The reaction mixture was evaporated under reduced pressure and the residue taken up in EA (5 mL 61, 162.11, 160.09, 155.28, 150.60, 148.63, 142.13, 135.39, 132.33, 128.81, 128.23, 123.26, 114.93, 114.76, 79.33, 67.12, 56.00, 55.55, 54.02, 47.41, 45.60, 39.09, 28.91, 28.64, 28.57 . HRMS calculated for C33H44N5O6 [M+H] + 606.3286, found m/z 606.3246.
Compound 23 detailed in manuscript.
trans-4-[6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8-
naphthyridine-3-amido]cyclohexyl 2-{[(tert-butoxy)carbonyl]amino}acetate (24)
A stirred solution of Boc-glycine (10 mg, 59 µmol) and TFFH (16 mg, 59 µmol) in anhydrous DCM (1.6 mL) was cooled to 0 °C and Et3N (41 µL, 0.30 mmol) was added. The mixture was warmed to rt and stirred for 30 min and then 21 (30 mg, 59 µmol) and DMAP (0.7 mg, 5.9 µmol) were added. The mixture was stirred for 14 h at rt and then evaporated under reduced pressure. The residue was taken up in EA (3 mL) 12, 162.56, 162.31, 160.13, 150.68, 148.61, 142.31, 135.48, 132.41, 128.84, 128.27, 123.22, 114.96, 114.80, 84.41, 69.94, 66.98, 55.91, 55.58, 53.90, 47.95, 47.47, 38.91, 34.03, 30.66, 28.47 cis-4-[6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 
naphthyridine-3-amido]cyclohexyl 7-{[(tert-butoxy)carbonyl]amino}heptanoate (25)
A solution of 20 (50 mg, 99 µmol), 7-{[(tert-butoxy)carbonyl]amino}heptanoic acid (48 mg, 0.20 mmol), TFFH (49 mg, 0.20 mmol), Et3N (137 µL, 0.99 mmol) and DMAP (1.2 mg, 9.9 µmol) in DCM (4 mL) was reacted as described in the procedure for 24. The crude residue was purified by flash silica column chromatography (1:2 hexane/EA) to yield 25 (48 mg, 66 µmol, 66%) as a yellow brown oil. 1 28, 162.66, 162.18, 160.14, 156.12, 150.67, 148.66, 142.30, 135.45, 132.41, 128.85, 128.27, 123.29, 114.97, 114.81, 69.19, 67.13, 56.06, 55.59, 54.06, 47.05, 40.68, 39.16, 34.74, 30.11, 29.84, 28.98, 28.66, 28.58, 27.84, 26.63, 25.14 
. HRMS-ESI calculated for C40H56N5O8
[M+H] + 734.4123, found m/z 734.4144. 4-[6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 47 (m, 8H, CH2), 1.44 (s, 9H, tBu CH3), 1.37 -1.30 (m, 4H, CH2 ). 13 C NMR (101 MHz, CDCl3) δ 173. 38, 162.58, 162.37, 160.14, 156.11, 150.69, 148.69, 142.26, 135.46, 132.39, 128.87, 128.28, 123.22, 114.97, 114.78, 71.78, 67.16, 56.05, 55.59, 54.07, 47.63, 40.66, 39.15, 34.67, 30.27, 30.07, 30.04, 28.92, 28.59, 26.60, 25 .07 (one quaternary carbon was not observed). HRMS-ESI calculated for C40H55N5O8 [M+H] + 734.4123, found m/z 734.4072. N-({[(1s,4s)-4-[6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2- 
trans-
naphthyridine-3-amido]cyclohexyl 7-{[(tert-butoxy)carbonyl]amino}heptanoate (26)
tert-Butyl
dihydro-1,8-naphthyridine-3-amido]cyclohexyl]carbamoyl}methyl)carbamate (27)
A solution of 22 (43 mg, 71.3 µmol) and TFA (0.3 mL) in DCM (3 mL) was reacted as described in the procedure for 12, to yield the TFA salt of 6-(4-methoxyphenyl)-1-[2- (m, 2H, CH2), 1.47 (s, 9H, tBu CH3) . 13 C NMR (101 MHz, CDCl3) δ 168. 81, 162.67, 162.22, 160.14, 156.30, 150.68, 148.65, 142.23, 135.46, 132.42, 128.82, 128.27, 123.24, 114.97, 114.80, 80.47, 67.14, 56.05, 55.58, 53.98, 46.50, 45.56, 44.85, 39.07, 29.83, 28.65, 28.49. HRMS calculated for C35H47N6O7 [M+H] + 663.3501, found m/z 663.3508. 6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 
cis-4-[
naphthyridine-3-amido]cyclohexyl 2-acetamidoacetate (28)
A solution of 23 (7.0 mg, 10.4 µmol) and TFA (0.2 mL) in DCM (0.8 mL) was reacted as described in the procedure for 12. The crude residue was purified by semi-preparative RP-HPLC to yield the TFA salt of cis-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) 6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 
trans-4-[
naphthyridine-3-amido]cyclohexyl 2-acetamidoacetate (29)
A solution of 24 (4.1 mg, 6.2 µmol) and TFA (0.2 mL) in DCM (0.8 mL) was reacted as described in the procedure for 12. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of trans-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) ethyl]- 2-oxo-1,2dihydro-1,8-naphthyridine-3-amido] 6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 
cis-4-[
naphthyridine-3-amido]cyclohexyl 7-acetamidoheptanoate (30)
A solution of 25 (22 mg, 29.6 µmol) and TFA (0.25 mL) in DCM (1 mL) was reacted as described in the procedure for 12. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of cis-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) 6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- 
trans-4-[
naphthyridine-3-amido]cyclohexyl 7-acetamidoheptanoate (31)
A solution of 26 (15 mg, 20.8 µmol) and TFA (0.25 mL) in DCM (1 mL) was reacted as described in the procedure for 12. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of trans-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) Compound 32 detailed in manuscript. 4-[6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- {4-[(E)-2-[2,2-difluoro-4-(thiophen-2-yl)-1λ4,3-diaza-2λ4-boratricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-12- 
trans-
naphthyridine-3-amido]cyclohexyl 2-[6-(2-
yl]ethenyl]phenoxy}acetamido)hexanamido]acetate (33)
The TFA salt of trans-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) ethyl]-2-oxo-1,2dihydro-1,8-naphthyridine-3-amido]cyclohexyl 2-aminoacetate (1.7 mg, 1.9 µmol), DIPEA (1.3 µL, 7.6 µmol), BODIPY 630/650-X-OSu (1.25 mg, 1.89 µmol) and DMF (721 µL) were reacted as described in the procedure for 16. The crude product was purified by semipreparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, yielding 33 (1.51 mg, 1.36 µmol, 72%) as a bright blue solid. HRMS-ESI calculated for C59H64BF2N8O9S [M+H] + 1109.4582, found m/z 1109.4580. Analytical RP-HPLC Rt = 20.39 min. 4-[6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- {4-[(E)-2-[2,2-difluoro-4-(thiophen-2-yl)-1λ4,3-diaza-2λ4-boratricyclo[7.3.0.0 3,7 ]dodeca-1(12),4,6,8,10-pentaen-12- 
cis-
naphthyridine-3-amido]cyclohexyl 7-[6-(2-
yl]ethenyl]phenoxy}acetamido)hexanamido]heptanoate (34)
A solution of 26 (15 mg, 20.8 µmol) and TFA (0.25 mL) in DCM (1 mL) was reacted as described in the procedure for 12. The crude was purified by semi-preparative RP-HPLC to yield the TFA salt of trans-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) 6-(4-Methoxyphenyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-1,8- {4-[(E)-2-[2,2-difluoro-4-(thiophen-2-yl)-1λ4,3-diaza-2λ4-boratricyclo[7.3.0.0 3,7 ]dodeca-1(12),4,6,8,10-pentaen-12- 
trans-4-[
naphthyridine-3-amido]cyclohexyl 7-[6-(2-
yl]ethenyl]phenoxy}acetamido)hexanamido]heptanoate (35)
The TFA salt of trans-4- [6-(4-methoxyphenyl)-1-[2-(morpholin-4-yl) ethyl]-2-oxo-1,2dihydro-1,8-naphthyridine-3-amido]cyclohexyl 7-aminoheptanoate (4.2 mg, 4.3 µmol), DIPEA (2.2 µL, 12.5 µmol), BODIPY 630/650-X-OSu (1.25 mg, 1.89 µmol) and DMF (735 µL) were reacted as described in the procedure for 16. The crude product was purified by semi-preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, yielding 35 (2.16 mg, 1.83 µmol, 97%) as a bright blue solid. HRMS-ESI
